Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Monday.

Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings

Crude Oil Down Over 2%; Delta Air Lines Posts Upbeat Earnings

U.S. stocks traded mostly higher midway through trading, with the Dow Jones index gaining more than 200 points on Thursday.

US Stocks Mixed; Initial Jobless Claims Fall

US Stocks Mixed; Initial Jobless Claims Fall

U.S. stocks traded mixed this morning, with the Dow Jones index gaining around 100 points on Thursday.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

1 Biotech Stock to Buy for 104% Upside Potential

Ultragenyx Pharmaceuticals is a beaten-down biotech stock trading at a steep discount to consensus price target estimates.

Benzinga's Top Ratings Upgrades, Downgrades For November 3, 2022

Benzinga's Top Ratings Upgrades, Downgrades For October 13, 2022

12 Health Care Stocks Moving In Tuesday's Intraday Session

inkl

Read news from The Economist, FT, and more,
with one subscription

What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

What 6 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:

Expert Ratings for Ultragenyx Pharmaceutical

Expert Ratings for Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter:

Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know

Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know

Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to $146.00. Shares of Ultragenyx Pharmaceutical are trading up 2.9% over the last 24 hours, at $53.30 per share.

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

Analysts have provided the following ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) within the last quarter:

Ultragenyx Pharmaceutical's Earnings Outlook

Ultragenyx Pharmaceutical's Earnings Outlook

Ultragenyx Pharmaceutical (NASDAQ:RARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Ultragenyx Pharmaceutical will report an earnings per share (EPS) of $-1.76.

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

What 4 Analyst Ratings Have To Say About Ultragenyx Pharmaceutical

Within the last quarter, Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings:

Where Ultragenyx Pharmaceutical Stands With Analysts

Where Ultragenyx Pharmaceutical Stands With Analysts

Ultragenyx Pharmaceutical (NASDAQ:RARE) has observed the following analyst ratings within the last quarter:

Get all your
news in one place.

100’s of premium titles.
One news app.

Ultragenyx Pharmaceutical: Q4 Earnings Insights

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Delta Air Lines

SherwinWilliams

B of A Securities

Truist Securities

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

318,586 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play